And due to it has broad pharmaceutical know-how, along with a real international market footprint, Pfizer matters a lot in the healthcare space, especially where metabolic treatment is concerned
If convenience is the main concern, both formats have practical merits
Because they're classed as food supplements, they don't go through the same safety checks as prescription medications
Figure 3
In 2025, the company reported a modest +1.29% YoY revenue growth, shaped largely by its core portfolio: Keytruda ($31.68B) continues to dominate as one of the worlds top-selling oncology drugs with expanding indications, Gardasil/Gardasil 9 ($5.23B) remains a key growth driver in vaccines despite some demand fluctuations, and Januvia/Janumet ($2.54B) continues to decline as generic competition intensifies
Any views expressed in this article reflect current scientific understanding as of the publication date and may evolve with further research